Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Buys 2,500 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 2,500 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was bought at an average cost of $12.51 per share, with a total value of $31,275.00. Following the acquisition, the chief executive officer now owns 5,552,502 shares of the company’s stock, valued at $69,461,800.02. This represents a 0.05 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Snehal Patel also recently made the following trade(s):

• On Tuesday, January 7th, Snehal Patel purchased 1,800 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $13.75 per share, with a total value of $24,750.00.
• On Thursday, January 2nd, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $11.97 per share, with a total value of $23,940.00.
• On Monday, December 30th, Snehal Patel purchased 3,200 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $11.12 per share, with a total value of $35,584.00.

Greenwich LifeSciences Trading Down 1.5 %

Shares of Greenwich LifeSciences stock traded down $0.18 during midday trading on Monday, reaching $12.20. The company had a trading volume of 17,633 shares, compared to its average volume of 45,222. The company has a market capitalization of $160.37 million, a price-to-earnings ratio of -15.25 and a beta of 1.66. The stock has a fifty day simple moving average of $13.13 and a 200 day simple moving average of $14.07. Greenwich LifeSciences, Inc. has a 1-year low of $8.00 and a 1-year high of $21.44.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of GLSI. Garden State Investment Advisory Services LLC bought a new position in shares of Greenwich LifeSciences during the third quarter worth $253,000. Barclays PLC boosted its position in shares of Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after purchasing an additional 6,538 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Greenwich LifeSciences by 4.6% during the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after purchasing an additional 5,861 shares in the last quarter. State Street Corp boosted its position in shares of Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after purchasing an additional 3,005 shares in the last quarter. Finally, Rhumbline Advisers bought a new position in shares of Greenwich LifeSciences during the second quarter worth $117,000. 4.16% of the stock is owned by institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.